JY
VTGN icon

Jeff Yass’s VistaGen Therapeutics VTGN Stock Holding History

Jeff Yass’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-142,607
Closed -$86K – 14636
2026
Q1 		$81.5K Sell
142,607
-192,179
-57% -$117K ﹤0.01% 12453
2025
Q4 		$222K Buy
334,786
+249,192
+291% +$900K ﹤0.01% 10651
2025
Q3 		$304K Sell
85,594
-29,774
-26% -$89K ﹤0.01% 10078
2025
Q2 		$231K Buy
115,368
+50,587
+78% +$115K ﹤0.01% 10917
2025
Q1 		$162K Sell
64,781
-31,125
-32% -$88.1K ﹤0.01% 11152
2024
Q4 		$283K Buy
95,906
+43,812
+84% +$123K ﹤0.01% 9956
2024
Q3 		$157K Sell
52,094
-13,013
-20% -$44.4K ﹤0.01% 10701
2024
Q2 		$227K Sell
65,107
-223,778
-77% -$969K ﹤0.01% 10073
2024
Q1 		$1.53M Buy
+288,885
New +$1.39M ﹤0.01% 5960
2023
Q4 		– Sell
-19,355
Closed -$73.2K – 13391
2023
Q3 		$101K Buy
19,355
+7,053
+57% +$31.3K ﹤0.01% 10908
2023
Q2 		$23K Buy
12,302
+8,294
+207% +$29.1K ﹤0.01% 11603
2023
Q1 		$15K Buy
4,008
+1,276
+47% +$6.69K ﹤0.01% 12120
2022
Q4 		$8.44K Sell
2,732
-3,277
-55% -$12.3K ﹤0.01% 11966
2022
Q3 		$27K Buy
6,009
+1,140
+23% +$11.3K ﹤0.01% 12493
2022
Q2 		$129K Buy
4,869
+682
+16% +$24.1K ﹤0.01% 11211
2022
Q1 		$156K Sell
4,187
-4,442
-51% -$194K ﹤0.01% 11526
2021
Q4 		$504K Buy
8,629
+2,008
+30% +$131K ﹤0.01% 9201
2021
Q3 		$544K Buy
6,621
+6,001
+968% +$521K ﹤0.01% 9158
2021
Q2 		$59K Sell
620
-7,796
-93% -$578K ﹤0.01% 12261
2021
Q1 		$538K Buy
+8,416
New +$562K ﹤0.01% 9296
2020
Q2 		– Sell
-660
Closed -$9K – 11009
2020
Q1 		$9K Buy
660
+204
+45% +$3.74K ﹤0.01% 10057
2019
Q4 		$9K Sell
456
-16
-3% -$404 ﹤0.01% 9556
2019
Q3 		$15K Buy
+472
New +$10.5K ﹤0.01% 9984
2018
Q3 		– Sell
-2,416
Closed -$99K – 10327
2018
Q2 		$99K Buy
+2,416
New +$84K ﹤0.01% 9045
2018
Q1 		– Sell
-27,810
Closed -$926K – 10271
2017
Q4 		$926K Buy
+27,810
New +$918K ﹤0.01% 5392

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Jeff Yass's VTGN Position: Q2 2026 in Review

Jeff Yass sold out of VistaGen Therapeutics (VTGN) in Q2 2026, closing a stake of 142,607 shares — an estimated $86K sold.

Jeff Yass first reported a position in VTGN in Q4 2017 and held it in 25 quarters. The position peaked at $1.53M in Q1 2024. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Jeff Yass reported no remaining VistaGen Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 142,607 VistaGen Therapeutics shares in Q2 2026, an estimated $86K.
  • Jeff Yass first reported a position in VistaGen Therapeutics in Q4 2017 and held it in 25 quarters.
  • Jeff Yass's VistaGen Therapeutics position peaked at $1.53M in Q1 2024.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.